CliffBio
small molecule

LACOSAMIDE

LACOSAMIDE

Loss of exclusivity—loss of exclusivity
CompanyNovitium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameLACOSAMIDE
Active ingredientLACOSAMIDE
Strength10MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2022
Marketing statusRX

More from Novitium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.